Oragenics
Manufacturing · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1990 Main St Ste 750, Sarasota, Florida,...Phone Number
(813) 286-7900Website
www.oragenics.comRevenue
<$5 MillionStock Symbol
OGENIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Oragenics
Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.Explore more
Oragenics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oragenics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Oragenics had a recent Job posting/layoffs
Check if Oragenics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Oragenics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Oragenics
Earning: See what the market has to say on Oragenics recently announced quarterly report
Oragenics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Oragenics launches new products
Check out if Oragenics is spiking on competitors!
Recommended Actions
Find VP level buyers at Oragenics
Find 3 more new buyers
Compare Similar Companies to Oragenics
Compare insights from companies similar to Oragenics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
1-10
Public
-
1982
MC
Michael CatelaniPresident & Chief Operating Officer & Chief Financial Officer
Company Profile Activity
Activity Insights
Oragenics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Oragenics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Oragenics.
Oragenics financials insights
Gather financial insights about Oragenics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$6M
2021
Share Placement
$21.9M
Oragenics Tech Stack
A closer look at the technologies used by Oragenics
Most Recent Scoops
Project
Product Development, Product Management, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Promotion
Executive Move
Executive Moves, Promotion
Executive Move
Executive Moves, Board of Directors
Lateral Move
Executive Move
Executive Moves, Lateral Move
Oragenics News & Media
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain BarrierOragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
SARASOTA, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that Alfred Hospital is now actively enrolling participants in its ongoing Phase IIa clinical trial evaluating ONP-002, the Company’s lead candidate for the treatment of concussion and mild traumatic brain injury (mTBI). To date, four patients have been enrolled andOragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stages
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oragenics
Sign Up For FreeTo access detailed company insights
Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from... Read More
